KW 2149

Drug Profile

KW 2149

Alternative Names: E 90/007; KT 6149

Latest Information Update: 26 Sep 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Cytostatic antibiotics; Mitomycins; Small molecules
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Sep 2006 Discontinued - Phase-II for Cancer in Japan (IV-injection)
  • 26 Sep 2006 Discontinued - Phase-III for Cancer in European Union (IV-injection)
  • 02 Oct 2001 No-Development-Reported for Cancer in European Union (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top